吉非替尼与化疗对晚期非小细胞肺癌患者的治疗效果

Therapeutic effect of gefitinib and chemotherapy on patients with advanced non-small cell lung cancer

目的探究吉非替尼与化疗对晚期非小细胞肺癌患者的治疗效果。方法选取2018年6月至2019年6月本院收治的40例晚期非小细胞肺癌患者作为研究对象,按患者就诊顺序奇偶性分为观察组与对照组,每组20例。对照组采用GP(吉西他滨+顺铂)化疗方案治疗,观察组采用吉非替尼治疗,比较两组临床疗效、疾病控制率、治疗前后外周血T淋巴细胞亚群CD3^(+)、CD4^(+)、CD8^(+)与表皮生长因子受体(EGFR)水平及药物不良反应发生率。结果两组治疗总有效率比较差异无统计学意义;观察组疾病控制率为90.00%,明显高于对照组的60.00%,差异有统计学意义(P<0.05)。治疗前,两组CD3^(+)、CD4^(+)、CD8^(+)及EGFR水平比较差异无统计学意义;治疗3个月后,观察组CD3^(+)、CD4^(+)水平均高于对照组,CD8^(+)、EGFR水平均低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论吉非替尼与化疗对晚期NSCLC患者均有明显治疗效果,但吉非替尼能更好地改善患者免疫细胞水平,降低EGFR水平,有效控制疾病进展,安全可靠,值得临床推广应用。

Objective To explore therapeutic effect of gefitinib and chemotherapy on patients with advanced non-small cell lung cancer.Methods 40 patients with advanced non-small cell lung cancer admitted to our hospital from June 2018 to June 2019 were selected as the research subjects,and they were divided into observation group and control group according to the parity of the patient’s order of treatment,with 20 cases in each group.The control group was treated with GP(gemcitabine+cisplatin)chemotherapy,and the observation group was treated with gefitinib.To compare the clinical efficacy,disease control rate,peripheral blood T lymphocyte subsets CD3^(+),CD4^(+),CD8^(+)and epidermal growth factor receptor(EGFR)content before and after treatment,and the incidence of adverse drug reactions between the two groups.Results There was no statistically significant difference in the total effective rate between the two groups;the disease control rate of the observation group was 90.00%,which was significantly higher than the 60.00%of the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of CD3^(+),CD4^(+),CD8^(+)and EGFR between the two groups.After 3 months of treatment,the levels of CD3^(+)and CD4^(+)in the observation group were higher than those in the control group,and the levels of CD8+and EGFR were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusion Gefitinib and chemotherapy have obvious therapeutic effects on patients with advanced non-small cell lung cancer,but gefitinib can better improve the level of immune cells in patients,reduce the level of EGFR,effectively control disease progression,it is safe and reliable,and is worthy of clinical application.